CoChat

Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies

Open access
Zhou, Dongyan, Chan, Jasper Fuk-Woo, Zhou, Biao, Zhou, Runhong, Li, Shuang, Shan, Sisi, Liu, Li, Zhang, Anna Jinxia, Chen, Serena J., Chan, Chris Chung-Sing, Xu, Haoran, Poon, Vincent Kwok-Man, Yuan, Shuofeng, Li, Cun, Chik, Kenn Ka-Heng, Chan, Chris Chun-Yiu, Cao, Jianli, Chan, Chun-Yin, Kwan, Ka-Yi, Du, Zhenglong, Lau, Thomas Tsz-Kan, Zhang, Qi, Zhou, Jie, To, Kelvin Kai-Wang, Zhang, Linqi, Ho, David D., Yuen, Kwok-Yung, Chen, Zhiwei · 2021 · Cell Host & Microbe
Cited by 102

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by a burst in the upper respiratory portal for high transmissibility. To determine human neutralizing antibodies (HuNAbs) for entry protection, we tested three potent HuNAbs (IC50 range, 0.0007–0.35 μg/mL) against live SARS-CoV-2 infection in the golden Syrian hamster model. These HuNAbs inhibit SARS-CoV-2 infection by competing with human angiotensin converting enzyme-2 for binding to the viral receptor binding domain (RBD). Prophylactic intraperitoneal or intranasal injection of individual HuNAb or DNA vaccination significantly reduces infection in the lungs but not in the nasal turbinates of hamsters intranasally challenged with SARS-CoV-2. Although postchallenge HuNAb therapy suppresses viral loads and lung damage, robust infection is observed in nasal turbinates treated within 1–3 days. Our findings demonstrate that systemic HuNAb suppresses SARS-CoV-2 replication and injury in lungs; however, robust viral infection in nasal turbinate may outcompete the antibody with significant implications to subprotection, reinfection, and vaccine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chom.2021.02.019

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 102

Metadata

Authors
Zhou, D., Chan, J. F.-W., Zhou, B., Zhou, R., Li, S., Shan, S., Liu, L., Zhang, A. J., Chen, S. J., Chan, C. C.-S., Xu, H., Poon, V. K.-M., Yuan, S., Li, C., Chik, K. K.-H., Chan, C. C.-Y., Cao, J., Chan, C.-Y., Kwan, K.-Y., Du, Z., Lau, T. T.-K., Zhang, Q., Zhou, J., To, K. K.-W., Zhang, L., Ho, D. D., Yuen, K.-Y., & Chen, Z.
Venue
Cell Host & Microbe
Publisher
Elsevier BV
Published
2021-04
Volume
29
Issue
4
Pages
551-563.e5
ISSN
1931-3128 (ISSN-L)
OpenAlex
W3131016929
Cited by
102
References
25
FWCI
7.18
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. https://app.cochat.ai/papers/10.1016/j.chom.2021.02.019
The paper
Zhou, D., Chan, J. F.-W., Zhou, B., Zhou, R., Li, S., Shan, S., Liu, L., Zhang, A. J., Chen, S. J., Chan, C. C.-S., Xu, H., Poon, V. K.-M., Yuan, S., Li, C., Chik, K. K.-H., Chan, C. C.-Y., Cao, J., Chan, C.-Y., Kwan, K.-Y., . . . Chen, Z. (2021). Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. Cell Host & Microbe. https://doi.org/10.1016/j.chom.2021.02.019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.